Home » Archemix Sells Hemophilia Drug Assets to Baxter for up to $305 Million
Archemix Sells Hemophilia Drug Assets to Baxter for up to $305 Million
Cambridge-based Archemix Corp. has agreed to sell all of its hemophilia-related assets to Illinois life sciences company Baxter International Inc. for a deal that could be worth up to $305 million for Archemix.
Mass High Tech
Mass High Tech
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May